Cargando…
Systematic Review With Meta-analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel Disease
BACKGROUND: Combining biologics and small molecules could potentially overcome the plateau of drug efficacy in inflammatory bowel disease (IBD). We conducted a systematic review and meta-analysis to assess the safety and effectiveness of dual biologic therapy (DBT), or small molecule combined with a...
Autores principales: | Alayo, Quazim A, Fenster, Marc, Altayar, Osama, Glassner, Kerri L, Llano, Ernesto, Clark-Snustad, Kindra, Patel, Anish, Kwapisz, Lukasz, Yarur, Andres J, Cohen, Benjamin L, Ciorba, Matthew A, Thomas, Deborah, Lee, Scott D, Loftus, Edward V, Fudman, David I, Abraham, Bincy P, Colombel, Jean-Frederic, Deepak, Parakkal |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8924906/ https://www.ncbi.nlm.nih.gov/pubmed/35310082 http://dx.doi.org/10.1093/crocol/otac002 |
Ejemplares similares
-
Nonalcoholic Fatty Liver Disease Is a Risk Factor for Thiopurine Hepatotoxicity in Crohn’s Disease
por: George, Alvin T, et al.
Publicado: (2023) -
Case Series: Re-induction of Intravenous, Weight-Based Ustekinumab Is Well Tolerated in Patients With Moderate–Severe Crohn’s Disease
por: Lee, Scott David, et al.
Publicado: (2022) -
Favorable Outcomes Combining Vedolizumab With Other Biologics or Tofacitinib for Treatment of Inflammatory Bowel Disease
por: Llano, Ernesto M, et al.
Publicado: (2021) -
Clinical Evaluation of Upadacitinib in the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis (UC): Patient Selection and Reported Outcomes
por: Irani, Malcolm, et al.
Publicado: (2023) -
Corticosteroids Increase the Risk of Invasive Fungal Infections More Than Tumor Necrosis Factor-Alpha Inhibitors in Patients With Inflammatory Bowel Disease
por: Gregory, Martin H, et al.
Publicado: (2023)